Chang T, Lin C, Wen S, Wu Y, Wei C, Huang J
Sci Rep. 2025; 15(1):8735.
PMID: 40082588
PMC: 11906863.
DOI: 10.1038/s41598-025-92697-z.
Ortega P, Bournique E, Li J, Sanchez A, Santiago G, Harris B
bioRxiv. 2024; .
PMID: 39605722
PMC: 11601322.
DOI: 10.1101/2024.11.14.623607.
Fabian Z, Kakulidis E, Hendriks I, Kuhbacher U, Larsen N, Oliva-Santiago M
Nat Commun. 2024; 15(1):6641.
PMID: 39103378
PMC: 11300803.
DOI: 10.1038/s41467-024-50912-x.
Szanto M, Yelamos J, Bai P
Expert Rev Mol Med. 2024; 26:e13.
PMID: 38698556
PMC: 11140550.
DOI: 10.1017/erm.2024.14.
Chatterjee P, Karn R, Isaac A, Ray S
Clin Transl Oncol. 2023; 25(11):3057-3072.
PMID: 37079210
DOI: 10.1007/s12094-023-03191-9.
Transcriptomic Analysis of CRISPR/Cas9-Mediated PARP1-Knockout Cells under the Influence of Topotecan and TDP1 Inhibitor.
Dyrkheeva N, Malakhova A, Zakharenko A, Okorokova L, Shtokalo D, Pavlova S
Int J Mol Sci. 2023; 24(6).
PMID: 36982223
PMC: 10049738.
DOI: 10.3390/ijms24065148.
PARP1 allows proper telomere replication through TRF1 poly (ADP-ribosyl)ation and helicase recruitment.
Maresca C, Dello Stritto A, DAngelo C, Petti E, Rizzo A, Vertecchi E
Commun Biol. 2023; 6(1):234.
PMID: 36864251
PMC: 9981704.
DOI: 10.1038/s42003-023-04596-6.
Targeting DNA-Protein Crosslinks Post-Translational Modifications.
Leng X, Duxin J
Front Mol Biosci. 2022; 9:944775.
PMID: 35860355
PMC: 9289515.
DOI: 10.3389/fmolb.2022.944775.
PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword.
Csizmar C, Saliba A, Swisher E, Kaufmann S
Cancers (Basel). 2021; 13(24).
PMID: 34945003
PMC: 8699275.
DOI: 10.3390/cancers13246385.
PARylation prevents the proteasomal degradation of topoisomerase I DNA-protein crosslinks and induces their deubiquitylation.
Sun Y, Chen J, Huang S, Su Y, Wang W, Agama K
Nat Commun. 2021; 12(1):5010.
PMID: 34408146
PMC: 8373905.
DOI: 10.1038/s41467-021-25252-9.
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance.
Rose M, Burgess J, OByrne K, Richard D, Bolderson E
Front Cell Dev Biol. 2020; 8:564601.
PMID: 33015058
PMC: 7509090.
DOI: 10.3389/fcell.2020.564601.
PARylation During Transcription: Insights into the Fine-Tuning Mechanism and Regulation.
Pahi Z, Borsos B, Pantazi V, Ujfaludi Z, Pankotai T
Cancers (Basel). 2020; 12(1).
PMID: 31940791
PMC: 7017041.
DOI: 10.3390/cancers12010183.
Topoisomerases and cancer chemotherapy: recent advances and unanswered questions.
Bjornsti M, Kaufmann S
F1000Res. 2019; 8.
PMID: 31602296
PMC: 6774054.
DOI: 10.12688/f1000research.20201.1.
Targeting Topoisomerase I in the Era of Precision Medicine.
Thomas A, Pommier Y
Clin Cancer Res. 2019; 25(22):6581-6589.
PMID: 31227499
PMC: 6858945.
DOI: 10.1158/1078-0432.CCR-19-1089.
Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib.
Augustine T, Maitra R, Zhang J, Nayak J, Goel S
Invest New Drugs. 2019; 37(5):948-960.
PMID: 30612311
DOI: 10.1007/s10637-018-00717-9.
DNA Damage-Response Pathway Heterogeneity of Human Lung Cancer A549 and H1299 Cells Determines Sensitivity to 8-Chloro-Adenosine.
Yang S, Li Y, An G, Ni J, Jia H, Li S
Int J Mol Sci. 2018; 19(6).
PMID: 29843366
PMC: 6032248.
DOI: 10.3390/ijms19061587.
Phase I study of veliparib in combination with gemcitabine.
Stoller R, Schmitz J, Ding F, Puhalla S, Belani C, Appleman L
Cancer Chemother Pharmacol. 2017; 80(3):631-643.
PMID: 28770300
PMC: 5734661.
DOI: 10.1007/s00280-017-3409-3.
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.
Konecny G, Kristeleit R
Br J Cancer. 2016; 115(10):1157-1173.
PMID: 27736844
PMC: 5104889.
DOI: 10.1038/bjc.2016.311.
Poly(ADP-ribose) polymers regulate DNA topoisomerase I (Top1) nuclear dynamics and camptothecin sensitivity in living cells.
Das S, Rehman I, Ghosh A, Sengupta S, Majumdar P, Jana B
Nucleic Acids Res. 2016; 44(17):8363-75.
PMID: 27466387
PMC: 5041477.
DOI: 10.1093/nar/gkw665.
Poly (ADP-ribose) polymerase inhibitors: recent advances and future development.
Scott C, Swisher E, Kaufmann S
J Clin Oncol. 2015; 33(12):1397-406.
PMID: 25779564
PMC: 4517072.
DOI: 10.1200/JCO.2014.58.8848.